Please Wait.....
Report
Global Intravenous Immunoglobulin - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-06-01 I 120 Pages I Mordor Intelligence
Global Intravenous Immunoglobulin Market Analysis
The intravenous immunoglobulin market size reached USD 16.31 billion in 2025 and is forecast to climb to USD 23.89 billion by 2030, translating into a 7.93% CAGR, which keeps the intravenous immunoglobulin market among the most resilient plasma-derived therapeutic spaces. Rising clinical use beyond primary immunodeficiency, demographic ageing, and sustained capacity investments by fractionators all reinforce demand fundamentals. North America leads the intravenous immunoglobulin market because of well-established reimbursement pathways and high per-capita spending, whereas rapid healthcare access gains and policy reform propel Asia-Pacific. IgG retains dominant status, and expanding neurological indications such as chronic inflammatory demyelinating polyneuropathy broaden the intravenous immunoglobulin market opportunity landscape.
Global Intravenous Immunoglobulin Market Trends and Insights
Rise in Geriatric Population
Age-related immune decline increases susceptibility to infections and autoimmune disorders, which sustains long-term demand within the intravenous immunoglobulin market. Asia-Pacific feels the effect most, as rapid population ageing aligns with broader diagnostic reach and insurance coverage. The demographic trend also amplifies secondary immunodeficiencies linked with cancer therapies, further lifting usage. Japan's medical technology spending trajectory underscores how ageing catalyzes specialty-therapy consumption. Together these factors form a predictable volume pipeline for fractionators over the next decade.
Increased Adoption of Immunoglobulin Therapy
Regulatory approvals such as Takeda's GAMMAGARD LIQUID for chronic inflammatory demyelinating polyneuropathy have validated broader immunomodulatory utility and accelerated clinician acceptance. Emerging data in autoimmune encephalitis and sepsis reinforce confidence, encouraging off-label prescribing as reimbursement loosens in several high-income markets. The evidence base unlocks new patient pools and extends dosing durations, thereby raising overall consumption inside the intravenous immunoglobulin market.
Stringent Regulatory Approval & Donor-Screening Norms
Tight donor eligibility rules and exhaustive validation steps lengthen lead times and add overhead, especially in the European Union and United States, where regulatory scrutiny remains intense. Batch-release requirements and viral safety benchmarks impose capital and documentation burdens that may decelerate new-entrant progress inside the intravenous immunoglobulin market.
Other drivers and restraints analyzed in the detailed report include:
Rising Prevalence of Immunodeficiency & Bleeding Disorders / Advancements in Plasma-Fractionation Technology / High Therapy & Cold-Chain Costs /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
IgG commanded 74.75% of the intravenous immunoglobulin market in 2024, and the segment is growing at an 8.54% CAGR to 2030, which underlines how indispensable IgG remains for both replacement and immunomodulation. Grifols' purification process consistently delivers ?98% IgG purity, strengthening brand differentiation. High-strength formulations now shorten infusion time, easing hospital scheduling pressures and improving patient comfort.
Manufacturers have prioritized continuous chromatography to boost yield and lower cost, which further bolsters margins across the intravenous immunoglobulin market. Regulatory clearances for new brands such as Yimmugo and ALYGLO increase competitive dynamics yet simultaneously assure broader supply security. IgA and IgM retain niche status focused on mucosal and complement-mediated disorders.
The Intravenous Immunoglobulin Market Report Segments the Industry Into by Type (IgG, Iga, Igm, and Others), by Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency, and More), End User (Hospitals, Specialty Clinics & Neurology Centers, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America kept 42.34% of the intravenous immunoglobulin market in 2024 due to long-standing insurer coverage and extensive plasma collection infrastructure. Medicare policies outline usage criteria that commercial payers largely mirror, facilitating predictable demand and rapid adoption of new formulations. Specialized infusion networks and maturing home-based services advance patient convenience and operational efficiency.
Asia-Pacific is growing fastest at an 8.45% CAGR through 2030. China's National Reimbursement Drug List negotiations produced average IVIG price reductions of 63% in 2024, opening therapy to previously unreachable cohorts. Japan's revised health technology assessments uphold funding for innovative biologics, while India's production-linked incentives stimulate local fractionation capacity, all of which enlarge the intravenous immunoglobulin market base.
Europe shows stable progression, yet supply dependence on United States plasma highlights vulnerability. ESG-driven self-sufficiency policies and centralized procurement place pressure on manufacturers to diversify donor pools and enhance transparency. Gradual shifts toward outpatient infusions aim to reduce hospitalization costs and maintain quality benchmarks across the intravenous immunoglobulin market.
List of Companies Covered in this Report:
Takeda Pharmaceutical Co. / CSL Behring / Grifols / Octapharma / Baxter / Kedrion Biopharma / Biotest / Bio Products Laboratory / LFB Group / China Biologic Products Holdings / Shanghai RAAS Blood Products / Hualan Biological Engineering / ADMA Biologics / Emergent Bio Solutions / Kamada Ltd / GC Biopharma / Intas Pharmaceuticals (Lonza Tie-up) / BioTest Pharma (US) / South African National Blood Service / Sanquin Plasma Products /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population
4.2.2 Increased Adoption of Immunoglobulin Therapy
4.2.3 Rising Prevalence of Immunodeficiency & Bleeding Disorders
4.2.4 Advancements in Plasma-fractionation Technology
4.2.5 Off-label Neurological Use & Relaxed Reimbursement in Asia
4.2.6 Regional Plasma-collection Hubs Driving Supply Security
4.3 Market Restraints
4.3.1 Stringent Regulatory Approval & Donor-screening Norms
4.3.2 High Therapy & Cold-chain Costs
4.3.3 Shift toward Subcutaneous Ig (SCIG) Reducing IVIG Volumes
4.3.4 ESG Scrutiny of Plasma Sourcing Raising Compliance Costs
4.4 Value / Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Threat of New Entrants
4.7.2 Bargaining Power of Buyers
4.7.3 Bargaining Power of Suppliers
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 Market Size & Growth Forecasts (Value - USD)
5.1 By Immunoglobulin Class
5.1.1 IgG
5.1.2 IgA
5.1.3 IgM
5.1.4 Others
5.2 By Application
5.2.1 Hypogammaglobulinemia
5.2.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
5.2.3 Primary Immunodeficiency Diseases (PID)
5.2.4 Myasthenia Gravis
5.2.5 Multifocal Motor Neuropathy
5.2.6 Other Applications
5.3 By End User
5.3.1 Hospitals
5.3.2 Specialty Clinics & Neurology Centers
5.3.3 Home-Care Settings
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles
6.3.1 Takeda Pharmaceutical Co.
6.3.2 CSL Behring
6.3.3 Grifols SA
6.3.4 Octapharma AG
6.3.5 Baxter International Inc.
6.3.6 Kedrion SpA
6.3.7 Biotest AG
6.3.8 Bio Products Laboratory Ltd
6.3.9 LFB Group
6.3.10 China Biologic Products Holdings
6.3.11 Shanghai RAAS Blood Products
6.3.12 Hualan Biological Engineering
6.3.13 ADMA Biologics Inc.
6.3.14 Emergent BioSolutions Inc.
6.3.15 Kamada Ltd
6.3.16 GC Pharma
6.3.17 Intas Pharmaceuticals (Lonza Tie-up)
6.3.18 BioTest Pharma (US)
6.3.19 South African National Blood Service
6.3.20 Sanquin Plasma Products
7 Market Opportunities & Future Outlook
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security